Search Results - john+isaacs

14 Results Sort By:
Mechanism-based 3rd Generation Quinoline-3-carboxamide HDAC4 Inhibitor for Metastatic Castration-resistant Prostate Cancer
Value Proposition:·        Metastatic castration-resistant prostate cancer (mCRPC) treatment that offers reduced side effects due to its mechanism of action (MoA)·        HDAC4 inhibition prevents the upregulation of stress survival pathways, which in turn may prevent metastases in mCRPC·        Similar anti-cancer agents must be dosed at lower concentrations...
Published: 3/14/2025   |   Inventor(s): John Isaacs, William Brennen, Emmanuel Akinboye
Keywords(s):  
Category(s): Clinical and Disease Specializations > Oncology > Prostate Cancer, Clinical and Disease Specializations > Oncology
Radiolabeled Thapsigargin Analogs Incorporated into Protease Activated Prodrugs
Various embodiments of this invention relate generally to targeted activation and delivery of therapeutic drugs to cells that produce prostate specific membrane antigen (PSMA), prostate specific antigen (PSA) or human glandular kallikrein 2 (hK2). Various embodiments relate more specifically to PSA, hK2 or PSMA-specific peptide prodrugs that become...
Published: 3/13/2025   |   Inventor(s): Soren Christensen, John Isaacs, Samuel Denmeade
Keywords(s): Biologics, Cancers, Disease Indication, Peptide, Prostate Cancer, Single, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer
Sequential Hormone Therapy to Improve Survival and Enhance Response to Immune Therapy in Men with Prostate Cancer
Unmet Need / Invention Novelty: Men with prostate cancer develop resistance to androgen deprivation therapy (castration resistant prostate cancer) and must rely on less defined subsequent lines of therapy. Increasing resistance develops with each subsequent line of hormonal therapy. There exists an unmet clinical need to overcome resistance to hormone...
Published: 3/14/2025   |   Inventor(s): Samuel Denmeade, John Isaacs, Emmanuel Antonarakis, Sushant Kachhap, Mark Markowski
Keywords(s):  
Category(s): Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Therapeutic Modalities
Novel prodrug strategy to improve clinical use of cancer drugs
Unmet Need / Invention Novelty: Clinical translation of various has been limited due to poor solubility and toxicity for repurposed anti-cancer applications. There exists an unmet need to develop new strategies to overcome these limitations. Technical Details: Researchers at Johns Hopkins have developed a novel prodrug strategy to improve solubility...
Published: 3/14/2025   |   Inventor(s): William Brennen, John Isaacs, Samuel Denmeade, Emmanuel Akinboye
Keywords(s):  
Category(s): Clinical and Disease Specializations > Oncology
Human Serum Albumin-PSA proaerolysin Prodrug
UNMET NEEDThe current standards of care for prostate cancer (Pca) include hormonal therapy, radiation therapy, surgery, chemotherapy, and combinational therapy. However, these treatments often have side effects that affect the quality of life of the Pca patients. Hence, there is an urgent need for developing better target-based therapies. This technology...
Published: 3/13/2025   |   Inventor(s): John Isaacs, Samuel Denmeade, William Brennen
Keywords(s): Biologics, Cancers, Disease Indication, Drug Delivery Vehicle, Peptides/Prodrugs, Prostate Cancer, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer
R-3327-AT6.3
Unmet NeedThere is increasing evidence supporting that ‘loss of function’ of metastasis suppressor genes plays an important role in cancer metastases. To help identify metastasis suppressor genes on human chromosomes, Johns Hopkins researchers have transferred individual human chromosomes into metastatic rat prostate cancer cells. Technology OverviewTo...
Published: 3/13/2025   |   Inventor(s): John Isaacs
Keywords(s): Basic Research Biomarker, Cancers, Cell Lines, Discovery/Research Tools, Disease Indication, Human Cell Lines, In Vitro Research Tool, Prostate Cancer
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Research Tools > Human Cell Lines, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools, Clinical and Disease Specializations > Oncology > Prostate Cancer
pAR-IRES-EGFP Plasmid
UNMET NEEDThe androgen receptor (AR) is a widely expressed ligand-activated transcription factor which mediates androgen signaling by binding to androgen response elements (AREs) in normal tissue and prostate cancer (PCa). Within tumors, the amount of AR plays a crucial role in determining cell growth, resistance to therapy and progression to fatal...
Published: 3/13/2025   |   Inventor(s): John Isaacs
Keywords(s): Basic Research Biomarker, Cloning Reagents, Discovery/Research Tools, Plasmid, Research Reagent
Category(s): Technology Classifications > Research Tools > Vectors & Plasmids, Technology Classifications > Research Tools
R-3327 AT.2
C03854: R-3327 AT.2 Technical Details: AT-2 originates from the spontaneous tumor (R3327) of the prostate identified by W.F. Dunning in a 22 month-old inbred Copenhagen male rat (1961). R3327 has been maintained by continuous serial passage in rats for many years. In 1974, a variant was characterized at Johns Hopkins (i.e. H for Hopkins). The H subline...
Published: 3/13/2025   |   Inventor(s): John Isaacs
Keywords(s): Basic Research Biomarker, Cancers, Cell Lines, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Mouse Cell Lines, Prostate Cancer, Rat Cell Lines
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Research Tools > Animal Models, Technology Classifications > Research Tools > Cell Lines, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools
R-3327 MAT-LyLu
C03853: R-3327 MAT-LyLu Technical Details: This cell line was derived from the "H" subline and upon passage to the AT-1 subline (JHU-29) of the parental R3327 tumor The "H" subline is a heterogeneous cell line as it is comprised of androgen-dependent and androgen-independent tumor cells. Passing this heterogeneous tumor cell...
Published: 3/13/2025   |   Inventor(s): John Isaacs
Keywords(s): Basic Research Biomarker, Cancers, Cell Lines, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Mouse Cell Lines, Rat Cell Lines
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools > Animal Models, Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Research Tools
R-3327-MAT-Lu
C03852: R-3327-MAT-Lu Technical Details: This cell line was derived from the "H" subline and upon passage to the AT-1 subline (JHU-29) of the parental R3327 tumor. The "H" subline is a heterogeneous cell line as it is comprised of androgen-dependent and androgen-independent tumor cells. Passing this AT-1 sublinein intactmale...
Published: 3/13/2025   |   Inventor(s): John Isaacs
Keywords(s): Basic Research Biomarker, Cancers, Cell Lines, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Mouse Cell Lines, Prostate Cancer, Rat Cell Lines
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Research Tools > Animal Models, Technology Classifications > Research Tools > Cell Lines, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools
1 2 
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum